San Francisco startup Construction Therapeutics is also working on an oral, after-day-to-day GLP-1 drug termed GSBR-1290—the drug surpassed Wall Road’s expectations in June each time a mid-stage research showed normal weight loss of close to 6% and it ideas to begin Yet another mid-phase trial toward the top of this year—that founder and CEO